Literature DB >> 17052340

Case report: rapidly fatal bowel ischaemia on clozapine treatment.

Giles Townsend1, David Curtis.   

Abstract

BACKGROUND: There have been previous reported deaths due to clozapine-induced constipation. In all these cases patients have experienced prior abdominal symptoms over a period of weeks or months. CASE
PRESENTATION: We report the sudden death due to constipation of a healthy young male patient on clozapine without any known history of prior abdominal symptoms.
CONCLUSION: Psychiatrists need to be alert to the medical emergencies which can occur in the context of clozapine treatment and also need to make other clinicians who may have contact with their patients aware of these.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052340      PMCID: PMC1621059          DOI: 10.1186/1471-244X-6-43

Source DB:  PubMed          Journal:  BMC Psychiatry        ISSN: 1471-244X            Impact factor:   3.630


Background

There have been six previously published cases of death secondary to clozapine-induced constipation [1-3]. Of these, two patients died from faecal peritonitis, two from aspiration of faeculent vomitus as a result of bowel obstruction and two from bowel necrosis. In all these cases there had been prior complaints of constipation and/or other abdominal symptoms for weeks to months before the fatal event. Here we describe a case of constipation, presumably clozapine-induced, where death from bowel ischaemia occured within 2 days from the first complaint of constipation and without any prior reported abdominal symptoms which might have provided a warning to the clinicians involved.

Case presentation

A 20-year-old male with a year long history of schizophrenia which had been unresponsive to trials of two atypical antipsychotic drugs was commenced on clozapine. The dose was titrated over the next year to 900 mg daily. Due to persisting negative symptoms amisulpiride 400 mg twice daily was added with good response after one month. The patient was reviewed regularly over the next year, continued to improve and did not report any side effects to members of the multidisciplinary mental health team working to support him in the community. He appeared to be fit and healthy. Although he usually lived in supported accommodation he was staying temporarily with his family and from their account he complained of having constipation for 2 days before presenting to his GP with severe abdominal pain. He was prescribed medication and returned home but his condition deteriorated further and a few hours later an ambulance was called. He collapsed and died before reaching hospital. Post mortem examination revealed that he had impacted faeces which had pressed against the bowel wall causing ischaemia. This had led to infarction of this part of the bowel.

Conclusion

This case demonstrates that death can occur over a very short time course from constipation, in this case presumably induced by clozapine. Death from constipation and subsequent bowel infarction is relatively common in elderly patients and infarction causes a far more rapid and dangerous deterioration than does intestinal obstruction. In the present case this meant that this patient did not have any contact with psychiatric services between the onset of his symptoms and his rapid demise, in spite of regular follow-up. Although the risk of neutropenia is relatively well-known, it should be borne in mind that clozapine is reported to be associated with a number of other syndromes which may be rapidly fatal including not only constipation and obstruction but also cardiovascular collapse, seizures and ketoacidosis. Psychiatrists working with such patients should not only themselves be vigilant regarding such complications but should take steps to see that other clinicians to whom the patient may present are also aware of them.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

Both authors were equally involved in the preparation of this manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:
  3 in total

Review 1.  Death from clozapine-induced constipation: case report and literature review.

Authors:  Tomer T Levin; Jonathan Barrett; Alan Mendelowitz
Journal:  Psychosomatics       Date:  2002 Jan-Feb       Impact factor: 2.386

2.  Clozapine and constipation: a serious issue.

Authors:  L Drew; P Herdson
Journal:  Aust N Z J Psychiatry       Date:  1997-02       Impact factor: 5.744

3.  Clozapine-induced constipation.

Authors:  G Hayes; B Gibler
Journal:  Am J Psychiatry       Date:  1995-02       Impact factor: 18.112

  3 in total
  6 in total

1.  Risk factors for ileus in patients with schizophrenia.

Authors:  Jimmi Nielsen; Jonathan M Meyer
Journal:  Schizophr Bull       Date:  2010-11-26       Impact factor: 9.306

2.  Life-threatening haematemesis associated with clozapine: a case report and literature review.

Authors:  Kazeem Olaide Adebayo; Nurudeen Ibrahim; Temilola Mosanya; Benjamin Eegunranti; Babatunde Suleiman; Akeem Ayankunle
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

3.  Clozapine-induced bowel infarction: a case report.

Authors:  Nicholas D McKinnon; Alvi Azad; Brian M Waters; Kaustubh G Joshi
Journal:  Psychiatry (Edgmont)       Date:  2009-03

Review 4.  Rare and very rare adverse effects of clozapine.

Authors:  Pasquale De Fazio; Raffaele Gaetano; Mariarita Caroleo; Gregorio Cerminara; Francesca Maida; Antonio Bruno; Maria Rosaria Muscatello; Maria Jose Jaén Moreno; Emilio Russo; Cristina Segura-García
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-06       Impact factor: 2.570

5.  Unrecognized clozapine-related constipation leading to fatal intra-abdominal sepsis - a case report.

Authors:  Vikram Oke; Frances Schmidt; Bikash Bhattarai; Md Basunia; Chidozie Agu; Amrit Kaur; Danilo Enriquez; Joseph Quist; Divya Salhan; Vijay Gayam; Prajakta Mungikar
Journal:  Int Med Case Rep J       Date:  2015-09-11

6.  Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service.

Authors:  Andrew Shaker; Rowena Jones
Journal:  Ther Adv Psychopharmacol       Date:  2017-11-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.